Vandetanib Demonstrates Anti-tumor Activity in RET-rearranged NSCLC

Share this content:
Treatment with vandetanib demonstrates anti-tumor activity and a manageable safety profile.
Treatment with vandetanib demonstrates anti-tumor activity and a manageable safety profile.

Among patients with advanced RET-rearranged non-small cell lung cancer (NSCLC), treatment with vandetanib demonstrates anti-tumor activity and a manageable safety profile, according to a study published in The Lancet Respiratory Medicine.1

Researchers led by Kiyotaka Yoh, MD, of the National Cancer Center Hospital East in Chiba, Japan, evaluated results from the phase 2 LURET trial, which enrolled 19 patients with advanced RET-rearranged NSCLC who received oral vandetanib continuously at 300 mg every day.

Seventeen patients were included in the primary analysis, of which 9 were able to achieve the primary endpoint of objective response. Nine patients achieved objective response in an intention-to-treat population analysis.

Median progression-free survival was 4.7 months at the data cutoff. Common adverse events included hypertension, diarrhea, and rash.

RELATED: Adding Nintedanib to Pemetrexed Prolonged PFS in Advanced Non-squamous NSCLC

“Our results define RET rearrangement as a new molecular subgroup of NSCLC suitable for targeted therapy,” the authors conclude.

Reference

  1. Yoh K, Seto T, Satouchi M, et al. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. Lancet Respir Med. 2016 Nov 4. doi: 10.1016/S2213-2600(16)30322-8 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters